A promising new targeted cancer therapy is now available to certain patients with advanced pancreatic cancer – from the comfort of their home. The treatment is available through a first-of-its-kind, entirely telehealth-based targeted cancer drug therapy nationwide clinical trial led by The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).

ARC Innovation at Sheba Medical Center and Icahn School of Medicine at Mount Sinai (part of the Mount Sinai Health System in New York City) today announced a landmark three-year collaboration with NVIDIA to harness the power of artificial intelligence for genomic discovery through the application of large language model (LLM) technology. The initiative aims to pioneer the decoding of the majority of the human genome that remains poorly understood in order to unlock new pathways for disease prevention, diagnosis, and treatment. Over the three-year period, the project will be supported by significant investment from the participating organizations, with the goal of accelerating research that can ultimately benefit patients worldwide.

A research team has tested how well three large language models can detect overlaps and redundancies in clinical questionnaires on mental illness / publication in ‘Nature Mental Health’

A new active substance attacks a key protein in tumour cells, leading to complete degradation. In cell experiments, this caused cancer cells to lose their protection and die. The active substance was developed by researchers at the Martin Luther University Halle-Wittenberg (MLU) and the University Medical Center Mainz. Other substances usually try to inhibit the activity of the protein “checkpoint kinase-1” (CHK1). However, if the protein is completely broken down, a chain reaction is triggered which leads to other tumour proteins being destroyed. Thus, the cancer cells are further weakened. The new study was published in the journal “Angewandte Chemie”.